It is a pleasure to serve under your chairmanship for the first time, Dr Huq, and I look forward to doing so on many more occasions. Addiction is a chronic condition with damaging consequences for individuals, their loved ones and wider society. A high proportion of prisoners already have substance misuse problems or develop addiction while incarcerated. The Government are committed to ensuring that people receive the treatment they need in prison to prevent reoffending. Investment in services has increased from £184 million in 2016-17 to £203 million in 2020-21, with a further £21 million over the next three years. The NHS is focusing on integrating substance misuse and mental health services, ensuring joined-up care for individuals entering or leaving prison. GP2GP functionality will enable GPs working in prisons to transfer clinical records to and from community GPs by June 2022, improving continuity of care. The Government accepted all key recommendations from Professor Dame Carol Black's independent review on drug misuse issues. An additional £780 million is available for enhancing drug treatment services and supporting offenders and ex-offenders. Both abstinence-based treatment and methadone prescribing have their place based on clinical evidence guidelines. Prisons White Paper aims to deploy full range of treatment options to support recovery from drug dependency, exploring the benefits of long-acting buprenorphine for prisoners and supplying naloxone medication to prevent opiate overdoses. NHS Reconnect service ensures no disruption to care pre-release, with an annual spend of £13.8 million in 2022-23 rising to £20 million in 2023-24. The focus on recovery is unprecedented in its ambition and funding, forming a key part of the Government's plans to cut crime and make communities safer.